Source: Financial Supervisory Service DART System / 2025-12-11
Disclosure Type: Decision on Acquisition of Other Corporation’s Shares and Investment Securities (Voluntary Disclosure) (Major Management Matters of Subsidiary) – Amendment
💡 3-Second Summary
Regarding Celltrion USA’s acquisition of Imclone Systems LLC from the counterparty Imclone Systems Holdings, Inc., the previously unconfirmed final acquisition date has been officially set for December 31, 2025.
📊 1. [Summary of Core Disclosure Content and Major Figures]
This amendment updates the voluntary disclosure originally submitted on September 23, 2025, regarding the decision to acquire shares and investment securities of another corporation.
- Key Amendment (Acquisition Date Confirmed): The expected acquisition date, which was previously left unconfirmed ( – ), has now been officially determined as December 31, 2025.
- Target Entity and Transaction Parties:
- Target Company (Issuer): Imclone Systems LLC (Nationality: U.S., Principal Business: Pharmaceutical Manufacturing, owning U.S. API facilities)
- Counterparty: Imclone Systems Holdings, Inc. (A subsidiary of Eli Lilly and Company. The parent company, Eli Lilly and Company, co-signed the agreement as a guarantor).
- Acquisition Amount and Ownership Stake:
- Acquisition Amount: KRW 460,020,000,000 (USD 330,000,000 / calculated using the initial base exchange rate of 1,394.00 KRW/USD on the original submission date of September 23, 2025).
- Ownership Stake Post-Acquisition: 100% (Since the target is a U.S. Limited Liability Company (LLC) without outstanding shares, the number of acquired shares is left blank).
- Acquisition Method: Cash Acquisition.
- Scope of Acquisition: The transaction is limited to Imclone Systems LLC excluding assets and liabilities other than the U.S. API production facilities. (The capital, sales, and net income of the specific acquisition target could not be separately identified and are not disclosed).
- Summary Financial Position of the Target Company (Adjusted for the acquisition scope):
- Current Year: Total Assets: KRW 488,876 million / Total Liabilities: KRW 33,038 million / Total Equity: KRW 455,838 million
📈 2. [Expert View: What This Disclosure Means for Investors]
This amendment indicates that the transaction date—previously unconfirmed at the time of the original filing due to ongoing external regulatory processes—has now been finalized.
- Finalization of the Expected Acquisition Date: As the acquisition date is confirmed for December 31, 2025, it implies that the administrative procedures have progressed to establish the final transaction execution timing. The officially stated purpose of this acquisition is ‘establishing local production infrastructure in the United States.’
- Timeline for Capital Outflow: The exact execution date for the KRW 460B cash acquisition has been set for December 31, 2025. Consequently, the short-term financial outflow schedule for the subsidiary and the consolidated entity has become specific.
- Potential for Adjustments: As noted in the disclosure, the expected acquisition date remains subject to change depending on the progress of external procedures such as regulatory approvals. Investors need to monitor whether the transaction formally closes by the specified date. The filing does not state specific future operating timelines or detailed business plans after the acquisition.
📝 Editor’s Comment (by K-STOCK Editor)
The final acquisition date for Celltrion USA’s contract to acquire Imclone Systems LLC has been finalized for December 31, 2025. This fills in the transaction date that was previously under adjustment due to administrative procedures during the initial voluntary disclosure.
The transaction is structured with the counterparty, Imclone Systems Holdings, Inc., being a subsidiary of Eli Lilly and Company, and Eli Lilly and Company co-signing the agreement as a guarantor. The acquisition amount is approximately KRW 460B, executed via cash acquisition without issuing common shares, and the number of shares is left blank as it involves acquiring a U.S. Limited Liability Company (LLC). The scope excludes assets and liabilities other than the U.S. API production facilities. Since the filing does not specify subsequent detailed operational plans or specific causes for future earnings changes, it is appropriate for investors to observe the timeline leading up to the transaction closing.
📢 Disclaimer & Sources
Source: This content was structured and newly written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Advisory: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
